Publications by authors named "Patrick Hallaert"
Article Synopsis
- - Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that responds well to radiation and has strong vaccine potential.
- - The main treatment for advanced MCC is immunotherapy, particularly immune checkpoint inhibitors, which may also be effective before or after surgery in high-risk patients.
- - New biomarkers are being researched to better identify high-risk patients and monitor them after treatment, but further studies are needed to find the best treatment strategies for those who do not respond to current immunotherapies.
The direct antitumour effects of mTOR inhibitors against cutaneous squamous cell carcinoma (SCC) have prompted a paradigm shift towards using sirolimus for allograft rejection prophylaxis in patients with high-risk SCC who have had a solid organ transplant (SOT). Patients who have had an SOT are at higher risk for Merkel cell carcinoma (MCC), yet there is little evidence concerning potential antitumour effects of immunosuppressive drugs against MCC. Screening seven immunosuppressive drugs in six MCC cell lines revealed that mycophenolate mofetil (MMF) had strong antitumour activity (surpassing mTOR inhibitors) and higher potency in MCC vs.
View Article and Find Full Text PDF